Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | HINT1 | P49773 | 2/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | KRAS | P01116 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480516 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL15588433 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL16480522 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL15588437 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL16480535 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL15588434 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL16777732 | 0.94 | CYP3A4 (0.59) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL16777474 | 0.94 | CYP3A4 (0.59) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL16777573 | 0.94 | CYP3A4 (0.59) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 | |
| SCHEMBL16777095 | 0.94 | CYP3A4 (0.59) | CYP3A4CYP2C9TAS1R3TAS1R1HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| WO-2014058801-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | CYP3A4 995/4885CYP2C9 612/4885TAS1R3 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.